



8th May 2025

Synairgen plc

SNG.AMPX

ISIN: GB00B0381Z20

“Shares Admitted to Trading on Asset Match Private Market”

Asset Match are delighted to welcome Synairgen to the platform and announce it's admission to the Asset Match Private Market. Please see their Admission Statement [here](#).

Asset Match, a firm authorised and regulated by the Financial Conduct Authority (FRN 579310), will operate an electronic off-market dealing facility for the Ordinary Shares. This facility will allow existing holders of Ordinary Shares in the Company ("Shareholders") and new investors to trade Ordinary Shares by matching buyers and sellers through periodic auctions.

The Ordinary Shares are admitted to trading at 0.95 pence per share and a market capitalisation of c.£10.47m. Auctions are scheduled to run semi-annually with the first set to close on Tuesday 30th September 2025 at 3pm.

The Asset Match trading facility operates under its own code of practice which governs the behaviour of participants and the running of the periodic auctions. Asset Match operates an open auction system where volumes of bids and offers at different prices are displayed on its website together with the closing date of the auction. At the end of each auction period, Asset Match passes this information through a non-discretionary algorithm that determines a "market-derived" share price based on supply and demand and allocates transactions accordingly. Bids and offers may be made and withdrawn at any time before the closing date of each auction.

Investors are encouraged to register on www.assetmatch.com and add [Synairgen](#) to their 'Watchlist' to receive Company updates and auction/price information.

Asset Match Limited

+44 (0) 207 248 2788
dealing@assetmatch.com

About Synairgen:

Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

About Asset Match:

Asset Match Limited, a firm authorised and regulated by the Financial Conduct Authority (FRN 579310), operates a leading online platform for trading unquoted securities. Established in 2012 they have become a trusted partner to a multitude of private companies, advisors, brokers and investors. The Asset Match model is to create secondary liquidity via periodic auctions where a live order-book is displayed throughout and a non-discretionary algorithm creates a single clearing price. The platform has facilitated over £130m of secondary transactions since inception.